Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
The American Surgeon|November 5, 2002
Can appendiceal CT scanning be utilized effectively in widespread general surgical practice?John McDonough, Chris Stasik, David Piontkowsky, et al.AIDS Reviews|May 20, 2016
Drug Interactions with Cobicistat- or Ritonavir-Boosted ElvitegravirThai Nguyen, Ian McNicholl, Joseph M Custodio, et al.Journal of the International AIDS Society|November 15, 2014
An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudineFelipe Rogatto, Stephane Bouee, Vivianne Jeanbat, et al.Journal of the International AIDS Society|November 15, 2014
Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysisHans-Juergen Stellbrink, Andrea Antinori, Anton Pozniak, et al.Plos One|July 9, 2016
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyJosep M Llibre, François Raffi, Graeme Moyle, et al.Plos One|May 20, 2016
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyJosep M Llibre, François Raffi, Graeme Moyle, et al.HIV Clinical Trials|December 1, 2014
Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studiesJonathan Winston, Michel Chonchol, Joel Gallant, et al.The Lancet. Infectious Diseases|June 9, 2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trialJose R Arribas, Gilles Pialoux, Joseph Gathe, et al.Journal of the International AIDS Society|November 15, 2014
Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 yearsBrian Gazzard, Pierre Marie Girard, Giovanni Di Perri, et al.The Lancet. HIV|October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trialFranco Maggiolo, Giuliano Rizzardini, François Raffi, et al.Pageof 3